Published in J Biol Chem on October 19, 2005
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem (2009) 2.05
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood (2007) 1.55
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov (2012) 1.25
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica (2011) 1.12
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem (2009) 1.07
Evaluating human cancer cell metastasis in zebrafish. BMC Cancer (2013) 1.06
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A (2014) 1.05
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One (2010) 1.04
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol (2013) 1.01
The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets (2011) 0.99
The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica (2009) 0.96
Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J Biol Chem (2010) 0.95
The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry (2010) 0.94
Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J Biol Chem (2010) 0.93
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia (2008) 0.93
Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. J Biol Chem (2008) 0.90
HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells. Cell Commun Signal (2009) 0.90
Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ. Biochem J (2010) 0.88
TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One (2012) 0.84
Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica (2011) 0.84
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN Oncol (2011) 0.83
The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT (2012) 0.82
A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens. J Cell Mol Med (2009) 0.81
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica (2015) 0.81
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget (2016) 0.80
Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia. BMC Cancer (2015) 0.79
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2011) 0.78
Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood (2015) 0.78
Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem (2015) 0.78
Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem (2015) 0.78
Erythropoietin and IGF-1 signaling synchronize cell proliferation and maturation during erythropoiesis. Genes Dev (2015) 0.77
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget (2017) 0.76
JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection, but not with α interferon therapy response in a Han Chinese population. Genet Test Mol Biomarkers (2012) 0.76
Two Dictyostelium tyrosine kinase-like kinases function in parallel, stress-induced STAT activation pathways. Mol Biol Cell (2014) 0.76
Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix. Biochem J (2016) 0.75
Elevated Serum Insulin-Like Growth Factor 1 Levels in Patients with Neurological Remission after Traumatic Spinal Cord Injury. PLoS One (2016) 0.75
Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion. PLoS One (2016) 0.75
Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Leukemia (2017) 0.75
Nuclear Import of JAK1 is Mediated by a Classical NLS and is Required for Survival of Diffuse Large B-cell Lymphoma. Mol Cancer Res (2016) 0.75
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
NetPath: a public resource of curated signal transduction pathways. Genome Biol (2010) 2.62
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol (2011) 2.50
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol (2008) 2.37
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development (2002) 2.16
A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood (2009) 2.08
The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem (2009) 2.05
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (2006) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood (2007) 1.83
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene (2004) 1.79
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med (2011) 1.78
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood (2008) 1.77
Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood (2010) 1.73
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood (2006) 1.71
MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood (2009) 1.70
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood (2007) 1.66
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood (2010) 1.64
Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood (2010) 1.63
Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum (2009) 1.62
Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood (2008) 1.61
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood (2012) 1.59
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med (2009) 1.58
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood (2006) 1.58
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood (2006) 1.56
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood (2006) 1.55
Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem (2008) 1.54
Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood (2013) 1.52
Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood (2005) 1.51
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica (2007) 1.51
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood (2005) 1.50
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood (2006) 1.50
Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res (2010) 1.47
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood (2009) 1.47
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol (2004) 1.46
Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood (2002) 1.45
Proplatelet formation is regulated by the Rho/ROCK pathway. Blood (2007) 1.44
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem (2005) 1.41
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood (2010) 1.41
Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle. Cell Res (2007) 1.40
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood (2006) 1.40
FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest (2004) 1.39
Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood (2011) 1.37
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood (2006) 1.35
Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem (2004) 1.33
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol (2008) 1.30
A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc Natl Acad Sci U S A (2009) 1.30
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood (2010) 1.28
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood (2008) 1.28
EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood (2008) 1.28
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood (2007) 1.27
Mechanisms of WASp-mediated hematologic and immunologic disease. Blood (2004) 1.26
Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood (2004) 1.25
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood (2013) 1.25
Intracellular localization and constitutive endocytosis of CXCR4 in human CD34+ hematopoietic progenitor cells. Stem Cells (2004) 1.24
Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood (2005) 1.23
RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nat Commun (2012) 1.22
Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood (2006) 1.21
BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol (2006) 1.21
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem (2008) 1.20
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood (2005) 1.20
Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat (2013) 1.18
New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood (2010) 1.18
The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood (2006) 1.17
Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med (2012) 1.16
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest (2014) 1.13
Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica (2011) 1.12
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood (2002) 1.12
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program (2005) 1.11
Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. Blood (2004) 1.11